SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Hiện đang được điều tra trong thử nghiệm then chốt Giai đoạn 2, CART-ddBCMA là liệu pháp tế bào T của Arcellx sử dụng chất kết dính tổng hợp mới của công ty, D-Domain. Kite và Arcellx sẽ cùng nhau thúc đẩy và thương mại hóa nội dung CART-ddBCMA ở Hoa Kỳ và Kite sẽ thương mại hóa sản phẩm bên ngoài Hoa Kỳ
Liệu pháp CAR T-Cell là một trong những phương pháp điều trị đột phá đối với một số loại ung thư máu. Có hơn 750 đang diễn ra các thử nghiệm lâm sàng in Liệu pháp CAR T-Cell ở Trung Quốc hiện tại. Bệnh nhân có nhu cầu đăng ký học có thể liên hệ ung thưFax đường dây trợ giúp bệnh nhân trên WhatsApp +91 96 1588 1588 hoặc email đến info@Cancerfax.com.
Giới thiệu về Arcell
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory đa u tủy (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk hội chứng loạn sản tủy, initiated in the fourth quarter of 2022.
Về Kite
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Giới thiệu về Khoa học Gilead
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences acquired Kite in 2017.
